Whitney L. Hensing, a prominent researcher from the University of Missouri KC School of Medicine, delves into the newly recognized category of HER2-low breast cancer. She discusses how this evolved classification impacts treatment decisions, particularly the role of novel therapies like antibody drug conjugates. Hensing highlights the significance of ongoing research improving diagnostics and access to therapies for this patient group, revealing a new frontier in breast cancer management that could change lives.